Source comparison
BPC-157 for Overtraining Syndrome Research: Comparison
Here's how BPC-157 for overtraining syndrome research compares to other peptide-based recovery interventions under investigation. BPC-157 VEGF upregulation, angiogenesis, fibroblast migration Rodent studies only; no human RCTs Theoretical HED: 200–500mcg; unva
This comparison does not assign a generated winner or score.
- Here's how BPC-157 for overtraining syndrome research compares to other peptide-based recovery interventions under investigation.
- BPC-157
- VEGF upregulation, angiogenesis, fibroblast migration
- Rodent studies only; no human RCTs
- Theoretical HED: 200–500mcg; unvalidated
- Addresses tissue microtrauma; does not address CNS or hormonal suppression
- Strong preclinical signal but lacks human validation. Useful for research contexts exploring tissue repair pathways
- TB-500 (Thymosin Beta-4)
- Actin regulation, cell migration, anti-inflammatory
- Limited human case reports; primarily equine and rodent data
- 2–5mg loading, 1–2mg maintenance (equine extrapolation)
- Similar tissue repair focus; no hormonal impact
- Comparable evidence gap to BPC-157. Both lack controlled human trials
- MK 677 (Ibutamoren)
- GH secretagogue; increases IGF-1 and growth hormone pulsatility
- Phase II human trials in sarcopenia and frailty
- 10–25mg oral daily
- Supports systemic recovery and lean mass retention; may address hormonal suppression in overtraining
- Only peptide in this table with Phase II human data. Stronger evidence base for systemic recovery
- Cerebrolysin
- Neurotrophic factors; supports neuroplasticity and CNS repair
- Human trials in stroke and TBI recovery; peptide fraction composition proprietary
- 10–30ml IV; multi-week protocols
- Addresses CNS fatigue component of overtraining. Distinct mechanism from tissue repair peptides
- Human evidence exists but in neurological contexts, not athletic recovery. CNS relevance to overtraining is theoretical
- The comparison underscores a recurring theme in peptide research for athletic recovery: preclinical models show compelling mechanisms, but human translation remains speculative. For labs investigating BPC-157 for overtraining syndrome research, the peptide represents a viable candidate for exploring tissue repair pathways. But expecting performance recovery without addressing training load, sleep architecture, and caloric sufficiency is mechanistically unsound.